8-K current report · filed Oct 8, 2026

Aardvark Therapeutics, Inc. (AARD) 8-K Current Report: October 8, 2026

Item 5.02Item 8.01Item EX-99.1AARD overview

Short answer

Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). David Zhang appointed Class II director, effective October 7, 2026.

Aardvark Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • David Zhang appointed Class II director, effective October 7, 2026
  • Biotech development expertise spanning Phase 3 trials, regulatory submissions and commercial-stage drug approvals
  • Annual cash retainer $40,000, prorated for service period
  • Appointment option valued at $500,000, vesting 1/36 monthly over 36 months
  • Full option vesting upon a qualifying change in control

Item 8.01 · Other Events

  • Dr. Zhang appointed to Aardvark Therapeutics’ Board effective October 8, 2026
  • Board addition may influence governance, strategic oversight, and investor confidence
  • Exhibit 99.1 contains the company’s announcement and appointment details

Item EX-99.1 · Exhibit EX-99.1

  • David Zhang appointed independent director effective October 7, 2026, strengthening clinical and regulatory expertise
  • More than 25 years’ experience across Abivax, Alumis, MyoKardia and Genentech/Roche
  • Board addition targets ARD-101 development and regulatory strategy for Prader-Willi Syndrome
  • FDA clinical hold on ARD-101 remains a key execution risk for investors

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aardvark Therapeutics, Inc. 8-K filings

Get the next AARD 8-K as it lands

Follow AARD for push alerts, or ask the research agent what this filing means.